Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Sponsor
Ruijin Hospital
Study ID
NCT04208347
Phase
PHASE2/PHASE3
Status
Active Not Recruiting

Conditions

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Key Dates

Start date
Dec 18, 2019
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
580 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib and Camrelizumab and S-1 and Oxaliplatin
  • Experimental: Apatinib and S-1 and Oxaliplatin
  • Active Comparator: S-1 and Oxaliplatin

Primary Outcome Measure

Pathological Complete Response (pCR) [ Time Frame: Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment ]

Related Studies